Leveraging its proprietary technology platforms, Alphamab Oncology has developed an exciting portfolio of pipelines with clear differentiation and global competitiveness. With clinically proven targets, CMC-validated manufacturing and global IP rights, Alphamab Oncology has created well-rounded pipeline projects with low risk and superb upside potential.
Recent progress in cancer immunotherapy has marked a historic breakthrough. At Alphamab Oncology, we have developed not only a well differentiated PD-L1 antibody (KN035), but also a potential backbone of next generation immuno-oncology therapy (KN046), representing a leap forward from currently available drugs on the market or in development.
Several other bispecific programs with best-in-class or first-in-class potential are also under development.